TipRanks
Go Ultimate55% OFF

Sipai Health Technology Co., Ltd. (0314) AI Stock Analysis

HK:0314

Sipai Health Technology Co., Ltd.

(HKEX:0314)

Select Model
Rating:49Neutral
Price Target:HKD 1.50â–²(7.14% Upside)
Action:reiterated
Date:09/06/26

The overall score is held down by weak financial performance and fragile cash flow despite a stronger balance sheet, while moderately positive technical momentum offers some support but a loss-making, non-dividend valuation keeps risk elevated.

Positive Factors
Improving Gross MarginImproved gross margin indicates better economics on the company’s remaining revenue base and may reflect cost actions or a more favorable mix. If sustained, this can support gradual earnings recovery, improve resilience during revenue normalization, and strengthen the path toward break-even.
Negative Factors
Sharp Revenue ContractionA steep revenue contraction weakens operating scale and makes fixed costs harder to absorb, limiting the benefit of improved gross margin. Continued top-line pressure could delay a return to profitability, reduce reinvestment capacity, and make earnings recovery dependent on uncertain growth stabilization.

Sipai Health Technology Co., Ltd. (0314) vs. iShares MSCI Hong Kong ETF (EWH)

-60%-40%-20%0%20%40%HK:0314-43.55%EWH+8.19%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.02B
Dividend Yield
―
Average Volume (3M)
783.32K
Price to Earnings (P/E)
-5.9
Beta (1Y)
0.33
Revenue Growth
-52.19%
EPS Growth
97.51%
Country
Hong Kong
Employees
3,131
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Sipai Health Technology Co., Ltd. Business Overview & Revenue Model

Company Description

Sipai Health Technology Co., Ltd. is a Chinese enterprise specializing in medical technology and health management. Its business operations are diversified across three primary divisions: Specialty Pharmacy, Physician Research Assistance, and Health...

Sipai Health Technology Co., Ltd. Financial Statement Overview

Summary

Financial performance is weak, with sharp revenue contraction, ongoing net losses, and poor cash generation partly offset by improved equity and low leverage.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.43B2.02B4.57B4.71B4.12B3.47B
Gross Profit332.69M277.08M386.43M414.70M337.35M281.06M
EBITDA-201.89M-74.82M-225.58M-189.21M-565.92M-665.44M
Net Income-317.52M-121.05M-323.74M-255.77M-1.37B-3.74B
Balance Sheet
Total Assets1.83B1.60B2.27B2.82B2.93B2.89B
Cash, Cash Equivalents and Short-Term Investments597.85M665.35M919.77M1.13B1.53B1.61B
Total Debt24.70M22.59M66.49M67.56M67.76M7.52B
Total Liabilities876.01M703.20M1.06B1.18B1.10B8.32B
Stockholders Equity995.88M936.71M1.23B1.62B1.84B-5.43B
Cash Flow
Free Cash Flow-124.99M127.00K-67.91M-139.24M-193.87M-643.33M
Operating Cash Flow-121.64M6.36M-59.45M-133.50M-182.07M-621.92M
Investing Cash Flow374.57M229.67M-622.00K-720.81M1.03B-1.02B
Financing Cash Flow-269.76M-218.77M-184.06M-120.55M81.69M559.29M

Sipai Health Technology Co., Ltd. Technical Analysis

Technical Analysis SentimentNeutral
Last Price1.40

Price Trends

50DMA1.50Negative
100DMA1.42Negative
200DMA1.74Negative

Market Momentum

MACD-0.03Negative
RSI48.46Neutral
STOCH72.60Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0314, the sentiment is Neutral. The current price of 1.40 is above the 20-day moving average (MA) of 1.39, below the 50-day MA of 1.50, and below the 200-day MA of 1.74, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.46 is Neutral, neither overbought nor oversold. The STOCH value of 72.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0314.

Sipai Health Technology Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:0314 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:2159HK:215956NeutralHKD 528.27M9.8228.00%―91.32%―
HK:9886HK:988656NeutralHKD 1.10B-15.19-3.87%―8.73%80.38%
HK:2251HK:225152NeutralHKD 904.97M-11.02-5.98%―10.67%57.27%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:9686HK:968651NeutralHKD 820.84M-48.06-5.98%―-3.77%73.89%
HK:0314HK:031449NeutralHKD 745.66M-5.94-11.19%―-52.19%97.51%
HK:2138HK:213841NeutralHKD 645.94M-1.52-25.36%―-8.94%-140.82%

* Healthcare Sector Average

Performance Comparison

-50%0%50%HK:0314HK:9886HK:2138HK:2159HK:2251HK:9686Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:0314 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:0314Sipai Health Technology Co., Ltd.1.40-1.13-44.66%
HK:9886Dingdang Health Technology Group Ltd.0.88-0.18-16.98%
HK:2138EC Healthcare0.52-0.13-19.53%
HK:2159Mediwelcome Healthcare Management & Technology Inc.1.600.3629.03%
HK:2251Beijing Airdoc Technology Co. Ltd. Class H9.08-3.61-28.45%
HK:9686NEUSOFT XIKANG HOLDINGS INC.1.030.088.42%

Sipai Health Technology Co., Ltd. Corporate Events

Sipai Health Tech Plans Major Disposal of Subsidiary Stake to Dashenlin

Oct 29, 2026

Sipai Health Technology has agreed through its wholly owned unit Sipai Investment to sell 100% of the equity in a wholly owned subsidiary, referred to as the Target Company, to Dashenlin for an aggregate consideration of RMB15 million, subject to an...

Sipai Health Technology Completes Acquisition of Jianyi Information Technology

Sep 10, 2026

Sipai Health Technology Co., Ltd. has completed the acquisition of 100% equity interest in Jianyi Information Technology (Shanghai) Co., Ltd. through its wholly owned subsidiary Bixun Pharmaceutical. The transaction, finalized on September 9, 2026, c...

Sipai Health Redeems RMB50 Million Wealth Product to Fund Acquisition

Aug 27, 2026

Sipai Health Technology’s subsidiary, Sipai Healthcare Investment, has redeemed a principal‑guaranteed cash management wealth management product from Industrial Bank, withdrawing RMB50 million on August 27, 2026, after subscribing on July...

Sipai Health Swings to Profit Despite Sharp Interim Revenue Decline

Aug 20, 2026

Sipai Health Technology Co., Ltd. reported a sharp drop in interim revenue for the six months ended June 30, 2026, with total revenue falling 39.6% year-on-year to RMB739.9 million. The decline was driven mainly by its specialty pharmacy business, wh...

Sipai Health Schedules Board Meeting to Approve Interim Results and Dividend

Aug 10, 2026

Sipai Health Technology Co., Ltd. has scheduled a board meeting for August 20, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The board will also consider whether to declare an interim dividend, a dec...

Sipai Health Technology Signals Profit Turnaround on Core Business Growth

Aug 4, 2026

Sipai Health Technology Co., Ltd., a Cayman Islands‑incorporated company listed in Hong Kong, focuses on healthcare‑related corporate insurance services and physician research assistance. Its strategy centers on expanding higher‑mar...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026